<DOC>
	<DOCNO>NCT00675545</DOCNO>
	<brief_summary>The primary objective determine efficacy docetaxel plus carboplatin first line treatment patient hormone refractory prostate cancer .</brief_summary>
	<brief_title>A Phase II Study Docetaxel Plus Carboplatin Chemonaive Hormone-Refractory Prostate Cancer ( HRPC ) Patients</brief_title>
	<detailed_description>Docetaxel-prednisolone current standard HRPC , base 2 large randomize trial show improved survival compare mitoxantrone-prednisolone . Carboplatin activity prostate cancer combination Docetaxel-carboplatin known synergistic use good effect many cancer . The advantage use combination prostate cancer suported clinical data : high response rate docetaxel-carboplatin-estramustine ( G-CSF support ) phase II trial ( Oh , Halabi , Kelly et al . Cancer . 2003 Dec 15 ; 98 ( 12 ) :2592-8 ) , additional effect combination prior taxane failure ( Oh , George , Tay . Clin Prostate Cancer . 2005 Jun ; 4 ( 1 ) :61-4 ) . Carboplatin activity theoretically could target hormone resistant clone neuroendocrine component tumor . ( Di Sant ' Agnese . J Urol . 1994 Nov ; 152 ( 5 Pt 2 ) :1927-31 . ) We study combination docetaxel-carboplatin give weekly , low-dose fashion , without estramustine without G-CSF . This expected effective tolerable treatment HRPC patient . We document ( knowledge ) first time trial efficacy combination give particular dose schedule .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma prostate . 2 . At time enrollment , patient must evidence metastatic disease , either measurable disease per RECIST criterion non measurable disease ( i.e . positive bone scan ) PSA &gt; 5 ng/mm3 . 3 . Disease progression follow androgen deprivation therapy . 4 . Progression define accord PSA Working Group criterion ( see 6.1.3 6.3 ) . 5 . Serum testosterone level &lt; 50 ng/mm3 ( unless surgically castrate ) . Patients must continue androgen deprivation LHRH analogue undergone orchiectomy . 6 . No use antiandrogen least 4 week . 7 . Have treat chemotherapy . 8 . ECOG performance status &lt; = 2 . 9 . Laboratory criterion entry : White blood cell ( WBC ) = &gt; 3000/mm3 Platelets = &gt; 100,000/mm3 AST &lt; 2.5 x upper limit normal Calculated CCT = &gt; 40 ml/min 10 . Signed informed consent form . 11 . Age : 30 year old 1 . Significant peripheral neuropathy define grade 2 high . 2 . Within 4 week since complete external beam radiotherapy 8 week since complete radiopharmaceutical therapy ( strontium , samarium ) . 3 . Concomitant chemotherapy investigational agent .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>